

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



INTERNATIONAL BUREAU OF PATENT COOPERATION
358, RUE DE LA FOIRE, CHAMBRÉY, CEDEX 03, 59201 LILLE, FRANCE


(43) International Publication Date
26 July 2001 (26.07.2001)

PCT

(10) International Publication Number
WO 01/53340 A2

- (51) International Patent Classification: C07K 14/435
- (21) International Application Number: PCT/US01/01740
- (22) International Filing Date: 19 January 2001 (19.01.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/177,319 21 January 2000 (21.01.2000) US
- (71) Applicant (for all designated States except US): PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): GURNEY, Mark, E. [US/US]; Tjarnagata 39, Reykjavik (IS). ABRAHAM, Irene [US/US]; 2576 Ninth Avenue West, Seattle, WA 98119 (US).
- (74) Agents: DELUCA, Mark et al.; Woodcock Washburn Kurtz Mackiewicz & Norris LLP, 46th Floor, One Liberty Place, Philadelphia, PA 19103 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, JP, KE, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TRANSGENIC MOUSE MODEL OF HUMAN NEURODEGENERATIVE DISEASE



(57) Abstract: This invention provides transgenic mice expressing wild-type or mutant isoforms of human tau protein. The transgenic mice of the invention have many uses, including screening candidate drug compounds effective against neurodegenerative diseases and other diseases involving tauopathies. The transgenic mice of the invention can also be used in genetic crosses with other transgenic mice strains to model the progression of neurodegenerative disease.

WO 01/53340 A2

TRANSGENIC MOUSE MODEL OF HUMAN NEURODEGENERATIVE DISEASE

CROSS-REFERENCE TO RELATED APPLICATIONS

5 This application claims priority to U.S. Provisional Patent Application, Serial
Number 60/177,319 filed January 21, 2000, which is hereby incorporated by reference.

FIELD OF THE INVENTION

 This invention is related to the fields of transgenic animals, neurodegenerative
10 disease, and of identifying compounds to treat such diseases.

BACKGROUND OF THE INVENTION

 Many neurological diseases such as Alzheimer's disease, frontotemporal dementia
and Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy,
15 corticobasal degeneration, and other undefined dementias, have the common pathological
feature of neurofibrillary tangles (NFTs). NFTs are structures made up of paired helical
filaments (PHFs), composed primarily of tau protein in a hyperphosphorylated state. Tau
belongs to a family of microtubule associated proteins (MAPs) that are thought to play
critical roles in stabilizing and remodeling the neuronal cytoskeleton. Under normal
20 physiological conditions tau is found primarily in the brain, associated with the cellular
cytoskeleton.

 The adult human brain expresses six different isoforms of tau protein, ranging in
size from 352 to 441 amino acid residues. The isoforms differ by having either three or
four microtubule binding domains, and by the presence or absence of amino-terminal
25 inserts. Tau is phosphorylated in the brain by a variety of kinases, although the
relationship between hyperphosphorylation and tangle formation is unclear. It is also

unclear how plaque and tangle formation leads to cognitive dysfunction and neuronal loss in patients with Alzheimer's disease.

Insight into the relationship of tau pathology and dementia has come through the study of FTDP-17, which is caused by mutations in the *tau* gene (see generally Goedert *et al.*, 1998, *Neuron* 21:955-958). The signature neuropathy associated with FTDP-17 is insoluble filamentous aggregates of hyperphosphorylated tau protein occurring in the absence of amyloid plaque and Lewy bodies, hallmarks of Alzheimer's disease and Pick's disease, respectively. Tau deposits are present not only in neurons, but also in large numbers of glial cells including predominantly oligodendrocytes, and also astrocytes (Spillantini *et al.*, 1997, *Proc. Natl. Acad. Sci. USA* 94:4113-4118). Many of the tau protein deposits also react with antibodies directed against ubiquitin. Immuno-electron microscopy demonstrates that tau is present as cytoplasmic filaments reminiscent of the paired helical filaments found in Alzheimer's disease, but these helical filaments have a different diameter and periodicity (Spillantini *et al.*, 1998, *Am. J. Pathol.* 153:1359-1363). Pathology varies between patients and may correlate with the particular *tau* mutation (Rizzu *et al.*, 1999, *Am. J. Hum. Genet.* 64:414-421).

Human tau protein has been expressed in transgenic mice in a number of studies. Gotz *et al.* (1995, *EMBO J.*, 14:1304-1313) used the human Thy-1 promoter to express, in transgenic mice, the longest isoform of wild-type human tau, which is 441 amino acids in length, containing the 58 amino acid amino-terminal insert and four microtubule binding domains. Brion *et al.* (1999, *Am. J. Pathol.* 154:255-270) used the murine 3-hydroxy-methyl-glutaryl CoA reductase (HMG-CR) promoter to express the shortest human tau isoform, which is 352 amino acids in length, contains no amino-terminal inserts, and has three microtubule binding domains. An increase in tau phosphorylation at sites associated with Alzheimer's disease pathogenesis is seen in both models, as shown by reactivity with the PHF1 and AT8 monoclonal antibodies that recognize phosphoepitopes on the tau protein. In the HMG-CR/*tau* mice, this increase in tau phosphorylation is accompanied by the formation of a conformation-dependent epitope associated with early Alzheimer's disease pathology (Brion *et al.*, *supra*). This epitope is detected with an antibody designated Alz50, raised against paired helical filaments purified from Alzheimer's disease brain. Neurofibrillary tangles were not present in either transgenic model.

Zahr *et al.* (1999, *Soc. Neurosci.* 25(A)447.1) have recently reported transgenic

expression in mice of mutant tau, containing the V337M mutation (*i.e.*, the valine at position 337 of the wild-type is replaced with methionine) in the context of a three microtubule binding domain isoform, under the regulatory control of the mouse prion promoter.

Additional transgenic models in which an increase in tau phosphorylation is seen include mice expressing mutant human amyloid precursor protein (APP) (Sturchler-Pierrat *et al.*, 1997, Proc. Natl. Acad. Sci. USA 94:13287-13292), glycogen synthase kinase-3 β (Brownlee *et al.*, 1997, Neuroreport 8:3251-3255), and the serine/threonine kinase Mos (James *et al.*, 1996, Neurobiol. Aging 17:235-241). Filamentous tau pathology is also absent from these models.

Considerable effort has been put into making transgenic models of human neurodegenerative disease based on expression in transgenic mice of pathogenic human mutations. Choice of mutation, choice of transgene vector, expression in appropriate types of neurons, and transgenic expression of the mutant human protein at sufficient levels are all critical to success. Strategies for creation of transgenic models have therefore varied widely. For example, the transgenic models for familial amyotrophic lateral sclerosis used the 12 Kb SOD1 gene for expression of human Cu,Zn superoxide dismutase containing the mutations G93A (Gurney *et al.*, 1994, Science 264:1772-1775) or G37R (Wong *et al.*, 1995, Neuron 14:1105-1116).

Transgenic models for amyloid β -peptide deposition in Alzheimer's disease have used either the platelet-derived growth factor promoter (Games *et al.*, 1995, Nature 373:523-527), insertion into the human prion gene (Hsiao, 1997, J. Neural. Transm. Suppl. 49:135-144), or the human Thy-1 promoter (Sturchler-Pierrat *et al.*, *supra*) to elicit transgenic expression of the amyloid precursor protein, containing either the "London" or "Swedish" mutations associated with familial, early-onset Alzheimer's disease. These types of transgenic mice are becoming extraordinarily valuable to the pharmaceutical industry for their use as "gatekeeper" models for preclinical evaluation of promising drug candidates. An example of such a use was the testing of riluzole in the transgenic model of amyotrophic lateral sclerosis, where it proved to have a beneficial effect (Gurney *et al.*, 1996, Ann. Neurol. 39:147-157). The drug later became the first to be approved by the Food and Drug Administration for the treatment of the human disease. Similar use is

being made of transgenic mice that model various aspects of Alzheimer's disease pathology.

The current transgenic models of Alzheimer's disease, which are based on expression of mutant human amyloid precursor protein, are incomplete models of the disease. Although they show amyloid β -peptide deposition in plaque, no neurofibrillary tangles are noted, nor is there extensive neuronal cell loss or consequent brain atrophy. Thus, the art is in need of new and/or better models of Alzheimer's disease as well as other neurodegenerative diseases. The present invention is directed to addressing these, and other needs.

SUMMARY OF THE INVENTION

This invention provides transgenic mice expressing wild-type or mutant isoforms of human tau protein. The transgenic mice of the invention can be used for screening candidate drug compounds, which may be effective against neurodegenerative diseases and other diseases involving tauopathologies. The transgenic mice of the invention can also be used in genetic crosses with other transgenic mice strains to model the progression of neurodegenerative disease.

In one aspect, the present invention is directed to a transgenic mouse expressing a human tau protein under the regulatory control of the mouse prion gene promoter. The human tau protein that is expressed in the transgenic mouse may be either wild-type or may contain a mutation. The mutation may be one previously identified in humans, or may be a novel mutation. The human tau protein expressed may be any of the six different isoforms.

The invention is also directed to the use of the transgenic mice of the invention as models of neurodegenerative disease.

In another aspect of the invention, the transgenic mice are used to discover drugs that modulate tau protein expression and/or activity.

These and other aspects of the invention are more fully described below.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a schematic of a *tau* transgene construct used to prepare a

transgenic mouse of the present invention. See also Table 3, *infra*.

Figure 2 shows immunoblot analyses of human tau protein expression in the brains of wild-type and two kinds of mutant *tau* transgenic mice. Mouse brain samples are identified by mouse transponder ID number (5 digit number) or by ear tag number (337 and 341) (see Table 4, *infra*). Samples 21080, 21089, 21096, 22410, 22418, and 22435 serve as controls without human tau protein expression, and are from non-transgenic litter mates of the transgenic mice. Mice with transponder numbers are the progeny of the original founder mice mated with (C57BL/6 x SJL)F1 partners; mice with three digit numbers are the founder mice.

DETAILED DESCRIPTION OF THE INVENTION

The invention provides transgenic mice, containing transgenes of human *tau*, and expressing human tau protein.

Transgenic animals contain within their genetic material some genetic information from another organism. For example, a transgenic mouse might have a human gene inserted into its genetic material. Such foreign genetic material is referred to as a transgene.

Transgenic mice can be generated in a number of manners known to those of skill in the art. Typically, a transgenic animal is generated according to the following basic steps: 1) engineer a nucleic acid construct with a promoter (regulatory sequences) and cDNA or gene sequences of interest; 2) linearize and inject the transgene construct into the pronuclei of embryos; 3) implant the embryos into the uterus of a pseudo-pregnant female; 4) screen the offspring that are born (the live pups in the case of mice) for the presence of the transgene; and 5) breed the transgene-positive pups (founders) to get transgenic "lines." Examples of these and related techniques are found in, e.g., Hogan, B., Costantini, F. & Lacy, E., eds., *Manipulating the Mouse Embryo: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1986), which is incorporated herein by reference in its entirety.

Tau is predominantly expressed in neurons; the protein is principally localized in the axons. Some expression has also been noted in oligodendrocytes and astrocytes. Six different isoforms of tau protein are expressed in the adult human brain. Each isoform is

generated by differential splicing of an RNA transcript from the single *tau* gene, located on chromosome 17. The six isoforms range in size from 352 to 441 amino acid residues. The isoforms differ by having either three or four microtubule binding domains (imperfect repeats of 31 or 32 amino acid residues) in the carboxy-terminus, and by the presence or
 5 absence of 29- or 58-amino acid inserts, of unknown function, in the amino-terminus.

Tau protein microtubule binding domains, which contain the core microtubule binding domain motif proline-glycine-glycine-glycine (PGGG), are designated R1, R2, R3, and R4, and are encoded by exons 9, 10, 11, and 12, respectively. Exon 10, which encodes amino acid residues 275 through 305, is alternatively utilized (present in three of
 10 the six isoforms), such that the R2 microtubule binding domain is present only in tau isoforms containing four repeats. Thus, the isoforms range in size from 352 amino acid residues (with no amino-terminal inserts and three microtubule binding domains) to 441 amino acid residues (with a 58 amino acid amino-terminal insert and four microtubule binding domains). Table 1 summarizes the features of the six human tau isoforms, which
 15 are designated "A" through "F." The isoforms may also be respectively referred to as numbers "1" through "6," or by their total length in amino acid residues.

Table 1: The Six Isoforms of Human Tau Protein:

	<u>N-Terminal Insert</u>	<u>Microtubule Binding Domains</u>	<u>Length (amino acids)</u>
20	A none	3	352
	B 29 amino acids	3	381
	C 58 amino acids	3	410
	D none	4	383
25	E 29 amino acids	4	412
	F 58 amino acids	4	441

In fetal brain, only the smallest isoform of tau ("A" in Table 1) is expressed. The amino acid residues in tau protein, regardless of isoform, are typically referred to by the
 30 position number they would have in the largest isoform ("F"), which has 441 residues. See Spillantini & Goedert, 1998, Trends Neurosci. 21:428-433.

The DFTF-17 associated mutations in *tau* provide an important entry point in the

study of neurofibrillary tangle formation as it relates to neuronal dysfunction and death. *Tau* mutations linked to FTDP-17 are either missense mutations (see Table 2), leading to substitution of one amino acid for another, or mutations in the 5' splice site of exon 10.

Most of the missense mutations associated with FTDP-17 occur in or near three of the four homologous microtubule binding domains within tau. Many of the missense mutations reduce the ability of tau to bind microtubules and to promote microtubule assembly in biochemical assays (Hong *et al.*, 1998, Science 282:1914-1917; Hasegawa *et al.*, 1998, FEBS Lett. 437:207-210). The arginine to tryptophan mutation at amino acid 406 (R406W), although linearly distant from a microtubule binding domain (residue 406 is encoded in exon 13, which does not contain a repeat), is believed to interfere with microtubule binding through a conformational change in the protein (Hong *et al.*, *supra*). The asparagine to lysine at 279 (N279K), proline to leucine at 301 (P301L), and serine to asparagine at 305 (S305N) mutations are seen only in four repeat-containing tau isoform proteins, as these residues are encoded by alternatively spliced exon 10. The valine to methionine at residue 337 (V337M) mutation is of particular interest, because it causes a tau pathology in the brain indistinguishable from that seen in Alzheimer's disease (Spillantini *et al.*, 1996, Acta Neuropathol. 92:42-48; Poorkaj *et al.*, 1998 Ann. Neurol. 43:815-825).

Table 2: *Tau* Missense Mutations Associated with FTDP-17

Codon*	Amino Acid Substitution	Location Within Tau Protein	Reference
272	Glycine → Valine (G272V)	R1 Microtubule Binding Domain	1
279	Asparagine → Lysine (N279K)	R1 Microtubule Binding Domain	2, 3, 7
301	Proline → Leucine (P301L)	R2 Microtubule Binding Domain	1, 2, 4, 7
305	Serine → Asparagine (S305N)	R2 Microtubule Binding Domain	3, 8
337	Valine → Methionine (V337M)	R3 Microtubule Binding Domain	5, 6, 7

406	Arginine → Tryptophan (N406W)	Carboxy-Terminal to R4 Microtubule Binding Domain	1, 7
-----	----------------------------------	--	------

* Numbering is based on the longest tau isoform, containing 441 amino acid residues.

1. Hutton *et al.*, 1998, Nature 393:702-705
2. Clark *et al.*, 1998, Proc. Natl. Acad. Sci. USA 95:13103-13107
3. Hasegawa *et al.*, 1999, FEBS Lett. 443:93-96
4. Dumanchin *et al.*, 1998, Hum. Mol. Genet. 7:1825-1829
5. Poorkaj *et al.*, *supra* (refers to codon based on numbering of a shorter tau isoform)
6. Spillantini *et al.*, 1998, Brain Pathol. 8:387-402
7. Hong *et al.*, *supra*
8. Iijima *et al.*, 1999, Neuroreport 10:497-501

Two studies have examined the effect of several tau mutants on microtubule structure after transfection of the *tau* genes into cells in culture (Dayanandan *et al.*, 1999, FEBS Lett. 446: 228-232; Arawaka *et al.*, 1999, Neuroreport 10:993-997). These studies show variable effects of the mutants on microtubule structure. Arawaka *et al.* (*supra*) showed that the presence of the V337M mutation results in fewer cell processes and reduced microtubule networks. Dayanandan *et al.* (*supra*) reported no differences in morphology with V337M, P301L or R406W, but did see differences in cell processes after treatment with cytochalasin B. In addition, Nacharaju *et al.* (1999, FEBS Lett. 447:195-199) have shown that mutants P301L, V337M and R406W cause an accelerated aggregation of tau into filaments *in vitro*.

A number of splice mutations have been identified in association with FTDP-17. These mutations are located in the 5' region of the intron immediately following exon 10 of the *tau* gene. The mutations are: G to A at nucleotide position +3 of the intron (Spillantini *et al.*, 1998, Proc. Natl. Acad. Sci. USA 95:7737-7741); A to G at +13 (Hutton *et al.*, 1998, Nature 393:702-705); C to T at +14 (Hutton *et al.*, *supra*, Clark *et al.*, *supra*, Hong *et al.*, *supra*); and C to T at +16 (Hong *et al.*, *supra*). These splice mutations all destabilize a potential stem-loop structure that may be involved in regulation of the alternative splicing of exon 10. This causes more frequent usage of the 5' splice site and

an increased proportion of *tau* transcripts that include exon 10 (Hutton *et al.*, *supra*). The increase in transcripts containing exon 10 presumably is mirrored by an increase in the proportion of tau protein containing four repeats of the microtubule binding domain. An increase in splicing of exon 10 is also seen with two of the tau missense mutations, 5 asparagine to lysine at residue 279 (N279K) and serine to asparagine at residue 305 (S305N), neither of which alters microtubule binding or assembly (Hasegawa *et al.*, 1999, *supra*).

Based on what is understood about the mutations associated with FTDP-17, two types of mutations are sufficient to cause tau neuropathology: (1) mutations that alter the 10 ability of tau to bind to microtubules and promote microtubule assembly; and (2) mutations that increase the proportion of tau protein containing four microtubule binding domains.

The present invention provides transgenic mice expressing human tau protein in either wild-type or mutant forms. In one embodiment of the invention, human tau protein 15 is expressed in transgenic mice under the control of regulatory sequences from the mouse prion (PrP) gene promoter region. Preferably such expression is directed to the brain. More preferably, the regulatory sequences include the 5' flanking sequence of the mouse prion gene promoter, the first exon, the first intron, and the initial noncoding portion of the second exon of the mouse prion gene.

20 In a preferred embodiment, the human tau protein that is expressed in the transgenic mice is the wild-type 383 amino acid isoform of the protein (isoform D). This isoform contains four microtubule binding domains (i.e., it utilizes exon 10), but has no amino-terminal insert; it is the shortest of the four repeat-containing isoforms.

In another embodiment of the invention, mutant human tau protein is expressed in 25 the transgenic mice of the invention. Preferably, the mutation is the V337M mutation in the 383 amino acid isoform of the human tau protein. Those of skill in the art will recognize that other mutations can be used in the context of any of the six different isoforms of tau.

The tau protein expressed in the transgenic mice of the invention may contain a 30 mutation known to be associated with FTDP-17, including, but not limited to, the G272V, N279K, P301L, S305N, V337M, and R406W missense mutations.

The invention also provides transgenic mice expressing mutant forms of human tau

protein, containing mutations other than those known to be associated with FTDP-17. Those of skill in the art will recognize that such mutations can be selected based on the locations of microtubule binding domains and other important features of the tau protein. Mutations to be incorporated into *tau* transgenes can be chosen based on predicted interference with tau function or analogy with disease-associated mutations. Such mutations can be tested for their effect on tau function by transfection studies on tissue culture cells. Those of skill in the art will recognize that any mutations in *tau* which modulate tau activity can be used in the transgenic mice of the invention.

Examples of amino acid residues in tau that can be mutated include residue 332, which is a proline in wild-type tau. Residue 332 is located in the core PGGG motif of the R3 microtubule binding domain. Mutation of residue 332 from proline to leucine (P332L), mimics the FTDP-17-associated alteration at residue 301 (P301L) in the core PGGG motif of the R2 microtubule binding domain. In a preferred embodiment of the invention, the mutant human tau expressed in the transgenic mice contains the P332L mutation in the 383 amino acid isoform of the protein.

A further embodiment of the invention includes transgenic mice expressing human tau protein containing a missense mutation at amino acid residue 364, where proline has been changed to leucine, resulting in alteration of the core PGGG motif of the R4 microtubule binding domain, also mimicking the FTDP-17-associated mutation, P301L.

In a preferred embodiment of the invention, the nucleotide sequence encoding the human tau protein is provided by a nucleic acid containing no intronic sequences. Other embodiments may include intronic sequences in the transgene to study the effect of mutations that occur in such intronic regions, for example, the mutation of G to A at position +3 in the intron immediately following exon 10. Thus, the invention also provides transgenic mice containing transgenes of human *tau* with intronic mutations.

In another embodiment, the transgenic mice of the invention are used as models of the progression of neurodegenerative disease or other diseases whose hallmark is neuronal cell death. Preferably, the transgenic mice of the invention will develop, with age, tau pathologies including tau hyperphosphorylation and filamentous aggregates of tau. Tau hyperphosphorylation may be revealed by immunostaining for tau phosphoepitopes such as those recognized by PHF1 or AT8 monoclonal antibodies. Filamentous tau neuropathology may be revealed by staining for ubiquitin immunoreactivity. More

preferably, the tau transgenic mice will display neuronal loss and cognitive dysfunction.

In another embodiment of the invention, transgenic mice expressing tau protein are used to screen for compounds that can be used to treat neurodegenerative disease.

It will be appreciated by those of skill in the art that the transgenic mice of the present invention are useful for analysis of neurodegenerative diseases involving tau pathologies. Such diseases involving tau pathology, collectively referred to as tauopathies, include, but are not limited to, Alzheimer's disease, Pick's disease, FTDP-17, progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD), Down's syndrome, Argyrophilic grain disease, amyotrophic lateral sclerosis/parkinsonism dementia complex of Guam, Non-Guamanian motor neurone disease with NFT, Niemann-Pick disease type C, subacute sclerosing panencephalitis, postencephalitic parkinsonism, dementia pugilistica, myotonic dystrophy, Gerstmann-Straeussler-Scheinker disease with tangles, prion protein amyloid antipathy, presenile dementia with tangles and calcifications, and Hallervorden-Spatz disease (Tolnay & Probst, 1999, Neuropathol. Appl. Neurobiol. 3:171-187).

Thus, in another embodiment, the invention is a model of neurodegenerative disease comprising any of the above described transgenic mice. In another embodiment, the transgenic mice of the invention are used in the screening of drug compounds to identify those capable of treating neurodegenerative disease.

In another embodiment, the transgenic mice of the invention are used in the screening of drug compounds to identify those capable of modulating the expression and/or activity of tau protein.

In another embodiment, the transgenic mice of the invention are used to screen for compounds that can be used to treat diseases that involve neuronal cell death.

Other embodiments of the invention will be readily understood by those of skill in the art.

The invention is further illustrated by way of the following examples, which are intended to elaborate several embodiments of the invention. These examples are not intended, nor are they to be construed, as limiting the scope of the invention. It will be clear that the invention may be practiced otherwise than as particularly described herein. Numerous modifications and variations of the present invention are possible in view of the teachings herein and, therefore, are within the scope of the invention.

EXAMPLES

Example 1: Preparation of Transgenic Vectors

Plasmid phgPrP, containing most of the mouse *PrP* gene 5' end and its 3' flanking sequences, was obtained from Marek Fischer, Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, CH-809 Zurich, Switzerland. Plasmid T43, containing the cDNA encoding the wild-type 383 amino acid isoform of human tau [SEQ ID NO:1] in the vector pSG5 (Stratagene, La Jolla CA; GenBank Accession AF013258), was obtained from Virginia Lee, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 34th & Spruce Street, Philadelphia, PA 19104.

The sequence of the phgPrP insert was confirmed by the DNA Sequencing Core (Pharmacia & Upjohn). The 14,214 base pair (bp) phgPrP insert sequence was verified by comparison with the 38,418 bp GenBank sequence deposit for the *Mus musculus* short incubation prion protein *Prnpa* gene (Accession Number U29186). The phgPrP insert sequence extends the GenBank deposit by 5,047 bp of 5' flanking sequence [SEQ ID NO:2]. The entire phgPrP insert was cloned into pBluescript KS+ (Stratagene, La Jolla, CA). The resulting construct was opened with KpnI to remove the *PrP* coding sequence and 3' flanking region of the mouse *PrP* gene. Amplification by polymerase chain reaction (PCR) was used to resynthesize the 3' mouse *PrP* flanking sequence such that it contained 5' KpnI and XhoI sites for cloning. This created the vector 97-1, used for subsequent steps in assembly of the *PrP/tau* transgene.

To assemble the *PrP/tau* transgene, the 97-1 vector was opened with XhoI and SalI. This retained the mouse *PrP* promoter and sequences through the initial, noncoding portion of *PrP* exon 2. SalI was used to excise the human *tau*-383 insert fused to the polyadenylation site from the pSG5 vector. After dephosphorylation of the 97-1 vector, the two DNAs were ligated and transformed into *E. coli* strain DH5 α (GIBCO/BRL, Gaithersburg, MD). Bacterial colonies were screened for directional ligation of the *tau* insert in the sense orientation by PCR using the primers

AGTAATTGAAAGAGCTCAGACGATG [SEQ ID NO:3] and
TGTCACCTCTTGGTCTTGGTGC [SEQ ID NO:4].

The V337M mutation was introduced into the *tau*-383 coding sequence by

mutagenesis of a 302 bp PstI-HindIII DNA fragment using PCR. The PCR reaction was carried out using: a primer positioned 5' of the PstI site having the sequence GTACTCCACCCAAGTCGCCGTC [SEQ ID NO:5], a short 3' reverse primer containing the HindIII site having the sequence GCAGCAGCATCGAAGCTTCTCAG [SEQ ID NO:6], and a longer reverse "patch" primer containing the V337M mutation having the sequence GCAGCAGCATCGAAGCTTCTCAGATTTTACTTCCATCTGGCCACCTCC [SEQ ID NO:7].

The P332L mutation was also introduced into the *tau*-383 coding sequence by mutagenesis using PCR. The PCR reaction was carried out using a forward primer having the sequence CCGCAAGAGCCGCTGCAG [SEQ ID NO:8], the SEQ ID NO:6 reverse primer, and a longer reverse "patch" primer containing the P332L mutation, having the sequence GCAGCAGCATCGAAGCTTCTCAGATTTTACTTCCACCTGGCCACCTCCTAGTTT ATGATGG [SEQ ID NO:9].

The PCR reaction was performed with an Advantage-HF™ high-fidelity PCR kit (Clontech, Palo Alto, CA), using the buffer supplied with the kit. The "patch" PCR primer was used at 1/100th the concentration of the short, flanking primers. Five cycles of (95°C for 45 seconds, 60°C for 2 minutes, 72°C for 3 minutes) followed by 20 cycles of (95°C for 45 seconds, 68°C for 3 minutes) were used for synthesis of the mutant fragment. To construct a mutant *tau*-383 insert, the PstI-HindIII fragment from wild-type *tau*-383 was exchanged for a mutant fragment. Proper introduction of mutations was confirmed by sequencing in the Pharmacia & Upjohn DNA sequencing core. The cDNA sequence for the V337M mutant of the 383 amino acid isoform is provided in SEQ ID NO:10. The cDNA sequence for the P332L mutant of the 383 amino acid isoform is provided in SEQ ID NO:11. The same procedure as described above for wild-type *tau* was used to assemble mutant inserts, *tau*-V337M and *tau*-P332L, into the *PrP* transgene vector. Table 3 presents the general features in the transgenic constructs used to generate *tau* transgenic mice. The features correspond to those depicted in Figure 1. The sequence for the entire 9990 nucleotide sequence of the *PrP/tau* transgene vector comprising wild-type 383 *tau* is provided in SEQ ID NO:15.

Table 3. General Features in the *PrP/tau* Transgene Vectors Used for Microinjection

Feature	Nucleotide Location	
PrP promoter	1-6197	(Nucleotides 1-5047 are designated SEQ ID NO:2)
PrP exon 1	6198-6270	
PrP intron 1	6271-8457	
PrP exon 2	8458-8527	
<i>tau</i> -383 cDNA	8528-9727	
poly(A) region	9728-9990	

Example 2: Generation and Screening of Transgenic Mice

The 10 Kb plasmid inserts were prepared for microinjection by the University of Michigan Transgenic Facility following standard protocols. They were injected into F2 fertilized mouse eggs from matings of F1 hybrid C57BL/6 x SJL mice. Progeny were genotyped by Taqman™ PCR using mouse genomic DNA prepared from tail biopsies using the Qiagen tissue kit according to manufacturer's instructions. Amplification was performed with the Taqman™ PCR Core Reagents Kit (PE Biosystems) using 50mM KCl, 10mM Tris-HCl, pH 8.3, 10mM EDTA, 60nM Passive Reference Dye 1, 5mM MgCl₂, 200μM each of dATP, dGTP and dCTP, 400μM dUTP, 200nM each primer, 100nM Taqman probe, 0.5 units uracil-N-glycosylase, and 1.25 units AmpliTaq Gold. Specific amplification of human *tau* DNA was performed using the primers G29-Fp GCATTGGAGACACCCCAG [SEQ ID NO:12], G29-Rp GCTTTACTGACCATGCGAGC [SEQ ID NO:13], and G29 Taqman™ probe with 5' and 3' colorimetric tags FAM-CTGGAAGACGAAGCTGCTGGTCACG-TAMRA [the nucleotide portion of which is designated SEQ ID NO:14] with the thermal cycling parameters, 50°C-2 minutes, 95°C-10 minutes, 40 cycles of [95°C-15 seconds, 60°C-1 minute], and 25°C hold. The starting amount of mouse genomic DNA template was 10ng. A standard curve was generated ranging 5 orders of magnitude from 10² to 10⁶ copies of linearized *PrP/tau* transgene plasmid DNA, which was diluted into mouse genomic DNA to give a final concentration of 10ng/μl. All reactions were performed in duplicate.

Multiple mice were generated from fertilized mouse eggs injected with wild-type

or mutant constructs. For each construct, several founder mice, carrying the *tau* transgene, were identified. Table 4 shows that the transgenic mice contained varying numbers of copies of the *PrP/tau* transgene, from which varying levels of transcript were expressed.

5 **Table 4: Summary of Analysis of Transgenic *Tau* Mice**

Transgene and founder mouse number	Mouse Id	Gene Copy #	<i>htau</i> RT-PCR levels copies/67ng total RNA positive RT sample	<i>htau</i> RT-PCR levels copies/67ng total RNA negative RT sample
TgN(<i>PrP/tau</i>) 355	21088	4.6	16,599	81
TgN(<i>PrP/tau</i>) 327	21097	2.6	5,402	13
TgN(<i>PrP/tau</i>) 326	21083	13.7	595	161
	21214	10.6	754	26
TgN(<i>PrP/tau</i> -V337M) 249	22419	2.4	33,671	6
	22420	2.6	26,912	20
TgN(<i>PrP/tau</i> -V337M) 250	22405	0.3	19,138	0
	22408	0.2	21,814	0
TgN(<i>PrP/tau</i> -V337M) 257	22436	0.9	10,755	2
	22437	0.2	8,842	1
TgN(<i>PrP/tau</i> -P332L) 337	337	16.8	ND [†]	ND
TgN(<i>PrP/tau</i> -P332L) 341	341	1.4	ND	ND

[†]Not determined.

10 Table 4 summarizes the analysis of the transgenic mice. The first column lists the transgene designation (TgN) and founder mouse number. The founder mice are indicated by the numbers 355, 327, 326, 249, 250, 257, 337 or 341, after the transgene name TgN(*PrP/tau*), TgN(*PrP/tau*-V337M) or TgN(*PrP/tau*-P332L). The second column lists the mouse identification (Id) number (either a 5-digit transponder number or a 3-digit founder number, as used in Figure 2). Mice with a 5-digit number are the progeny of the founder mouse indicated in the first column by the three digit number after the transgene

name. The third column lists the haploid copy number of the human *tau* (*htau*) transgene, based on DNA levels derived after PCR analysis. This number was measured either in the founder or founder progeny, as indicated in the second column. The fourth column lists the human *tau* (*htau*) transgene mRNA expression, as determined by reverse transcriptase-PCR (RT-PCR). The fifth column lists the background amplification of the RNA samples, without conversion to cDNA by RT.

Example 3: Human Tau Expression

Mouse brain samples were harvested after intracardiac perfusion with cold phosphate-buffered saline, for analysis of human *tau* mRNA and tau protein expression. For cardiac perfusion, mice were deeply anesthetized, then perfused transcardially until the effluent was cleared of blood. Tissue samples were frozen immediately on dry ice, then stored at -70°C until analysis.

Total RNA was prepared from homogenized cortical brain tissue using the RNeasy mini kit (Qiagen). The RNeasy protocol was modified by the addition of the RNase-free DNase set protocol (Qiagen) to treat the RNA, while bound onto the column, with RNase-free DNase I at room temperature for 15 minutes to 1 hour, to remove any residual genomic DNA contamination. Two micrograms of total RNA was converted to cDNA in a 30µl reaction containing, 50mM Tris-HCl, pH 8.3, 75mM KCl, 3mM MgCl₂, 500µM each dNTP, 0.5µg random hexamers, 30 units RNase inhibitor, and 400 units Superscript II reverse transcriptase (RT), which was incubated at 42°C for 1 hour. The Superscript II RT enzyme was then heat inactivated by incubation at 95°C for 5 minutes. To assess the extent of genomic DNA contamination in the total RNA samples, control reactions, without RT, were also performed for each sample.

For determination of human *tau* mRNA expression, PCR amplification on the ABI PRISM 7700 instrument was performed using 2X Taqman™ universal PCR master mix (PE Biosystems) containing 200nM G29Fp and 200nM G29Rp primers and 100nM G29 Taqman probe. The final PCR reaction volume was 25µl, and contained 5µl of a 1:5 dilution of the cDNA reaction described above. The thermal cycling parameters were as follows, 50°C-2 minutes, 95°C-10 minutes, 40 cycles of [95°C-15 seconds, 60°C-1 minute], and 25°C hold. A relative standard curve was generated ranging 5 orders of magnitude

from 10^2 to 10^6 copies of linearized *PrP/tau* transgene plasmid DNA, which was diluted into mouse genomic DNA to a final concentration of 10ng/ μ l. All samples were run in either duplicate or triplicate.

For determination of human tau protein expression by immunoblot analysis, brain tissue was minced in 600 μ l lysate buffer (0.1M MES, pH 6.8, 0.75M NaCl, 0.5mM EGTA, 2mM DTT, 2mM PMSF, 10 μ g/ml aprotinin, 10 μ g/ml leupeptin, 10 μ g/ml soy bean trypsin inhibitor, 5 μ g/ml pepstatin) on ice. Brain fragments were ground with 10 strokes of a pestle in a pre-chilled TenBroeck tissue homogenizer. Lysate was centrifuged at 40,000g for 15 minutes at 4°C. Protein concentration of supernatants was determined by Bio Rad protein assay, and lysates were stored at -80°C until used.

50 μ g samples of the brain lysates were diluted into 4X gel loading buffer (250mM Tris-HCl, pH 6.8, 8% SDS, 20mM EDTA, 40% glycerol, 0.02% bromophenol blue, 20% β -mercaptoethanol), heated at 100°C for 5 minutes, and electrophoretically separated on a 7.5% polyacrylamide gel in running buffer (25mM Tris base, 192mM glycine, 0.01% SDS). The proteins were transferred to Nitrobind nitrocellulose membrane (Micro Separations Inc, Westborough, MA) in transfer buffer (25mM Tris base, 192mM glycine, 20% methanol). The membranes were blocked for 1 hour in PBS containing 5% nonfat dry milk. Blots were probed overnight at 4°C with either the T14 or HT7 anti-human tau antibody (Zymed Laboratories, Inc., So. San Francisco, CA), diluted to 2 μ g/ml in a solution of 10mM Tris-HCl, pH 7.5, 500mM NaCl, and 0.1% Tween 20 (TNTween), plus 1% BSA and 3% dry milk. After washing in TNTween, the blots were incubated for 1 hour at room temperature with goat anti-mouse, horseradish peroxidase-conjugated secondary antibody (Kirkegaard and Perry Laboratories, Inc., Gaithersburg, MD) at 1:5000 dilution. The immunoblots were washed again in TNTween, treated with ECL reagents for 1 minute, and exposed to X-ray film.

Progeny of the transgenic founders (mated to F1 hybrid (C57Bl/6 x SJL) partners) or the founders were analyzed for *PrP/tau* transgene expression in the brain. Both human *tau* mRNA (Table 4) and protein (Figure 2) were detected. Efficient, relatively high levels of human tau protein expression were obtained in transgenic mice using a mouse *PrP* gene vector coupled to a heterologous human *tau*-383 cDNA. Roughly equivalent levels of protein expression were obtained from wild-type and mutant *PrP/tau* transgenes,

suggesting that expression of mutant tau protein is relatively well tolerated in the mouse. The levels of expression achieved appear to be higher than those reported by Gotz *et al.*, *supra* or Brion *et al.*, *supra*, although different antibodies and methods of analysis were used to establish levels of protein expression. Ranking by protein expression roughly correlates with the PRISM measurement of mRNA expression.

Example 4: Microtubule Organization in GFP-*tau* Transfected Cells

To investigate the effect of mutations in the microtubule binding domains on tau protein interaction with microtubules, human embryonic kidney HEK293 cells were transiently transfected with cDNA encoding the 383 human tau isoform fused to green fluorescent protein (GFP). Wild-type and the P332L, V337M, and P301L *tau* mutants were analyzed. Fluorescence and biochemical analyses showed that GFP-labeled mutant tau proteins P332L, V337M, and P301L have an altered intracellular distribution, as compared to GFP-wild type tau protein.

Studies using an anti-tubulin antibody revealed that GFP-wild-type tau protein co-localizes with microtubules. Some tau protein is also present in the cytoplasm, not associated with microtubules. In cells expressing high levels of wild-type tau, a reorganization of the microtubule cytoskeleton was observed. Bundles of microtubules could be seen, often in the form of a spiral or a ring around the circumference of the cell. This is a phenomenon previously noted in non-neuronal cells expressing tau. Cells expressing low levels of GFP-wild type tau protein, contained a fine network of microtubules, often emerging from microtubule organizing center.

Cells expressing GFP-labeled mutant tau proteins P332L, V337M, and P301L exhibited higher levels of fluorescence dispersed in the cytoplasm than did cells expressing GFP-wild type tau protein. The microtubule bundling and the microtubule network, seen in GFP-wild type tau expressing cells, was also reduced in cells expressing the mutant tau proteins.

Immunoblotting analyses of cytosolic and cytoskeletal cellular fractions confirmed the fluorescence studies, showing that cells expressing the GFP-mutant tau proteins contained more tau protein in the cytosol than did cells expressing GFP-wild type tau. The difference was most dramatic for P332L, but the studies have confirmed that these

microtubule binding domain mutations interfere with tau protein interaction with microtubules.

Example 5: Cellular Analysis of Tau Transgenic Mice

- 5 General pharmacokinetic studies are used to analyze human tau expression in the transgenic mice. Pharmacokinetic studies include determination of the brain distribution of tau protein expression, and kinase activity assays. The state of phosphorylation of the tau protein is detected using monoclonal antibodies to specific phosphoepitopes of tau, including PHF1 and AT8, and various polyclonal antibodies. Filamentous tau
10 neuropathology is revealed by staining for ubiquitin immunoreactivity.

Example 6: Analysis of Neurodegenerative Disease in Transgenic Mice

- Neurodegenerative disease is studied in *tau* transgenic mice by use of a variety of behavioral studies, including the Morris water maze test, mobility and gait tests, and
15 behavioral observation (see, e.g., Moechars et al., 1999, Biol. Chem. 274:6483-6492).

Example 7: Drug Screening in Transgenic Mice

- The transgenic mice are used for the screening of compounds that affect tau hyperphosphorylation, filament formation, or neurodegenerative disease criteria.
20 Compounds that inhibit kinase activity, protease activity, phosphatase activity, oxidative stress reactions, apoptosis, or protein aggregation are tested for their ability to modulate 1) tau phosphorylation, 2) tau aggregate formation, 3) formation of cellular inclusions of paired helical filaments of tau, and 4) formation of neurofibrillary tangles in the transgenic mice. Those compounds exhibiting positive effects in such tests may be useful in the
25 treatment of neurodegenerative diseases.

All references cited herein are incorporated herein in their entirety by reference.

We claim:


1. A transgenic mouse, comprising a transgene, said transgene comprising a polynucleotide encoding a human tau protein operably linked to at least a portion of a regulatory region of a mouse prion gene, wherein said transgenic mouse expresses human tau protein.
2. The transgenic mouse of claim 1, wherein said human tau protein is selected from the group consisting of isoforms 352, 381, 410, 383, 412, and 441.
3. The transgenic mouse of claim 2, wherein said human tau protein is isoform 383.
4. The transgenic mouse of claim 1, wherein said human tau protein is selected from the group of mutants consisting of G272V, N279K, P301L, S305N, V337M, and R406W.
5. The transgenic mouse of claim 4, wherein said human tau protein is a V337M mutant of isoform 383.
6. The transgenic mouse of claim 2, wherein said human tau protein is further selected from the group of mutants consisting of G272V, V337M, and R406W.
7. The transgenic mouse of claim 3, wherein said human tau protein is further selected from the group of mutants consisting of N279K, P301L, and S305N.
8. The transgenic mouse of claim 2, wherein said human tau protein is mutant P332L.
9. The transgenic mouse of claim 1, wherein said human tau protein is expressed in the brain.

10. The transgenic mouse of claim 1, wherein said regulatory region comprises said prion gene promoter and 5' flanking sequence, the first *PrP* exon, the first *PrP* intron, and the initial, noncoding portion of the second *PrP* exon.
11. A model of neurodegenerative disease comprising a transgenic mouse as in any of claims 1-10.
12. The model of neurodegenerative disease of claim 11 for use in the screening of drugs to treat said disease.
13. The model of neurodegenerative disease of claim 11 for use in genetic crosses to generate models of Alzheimer's disease.
14. A method of screening for a drug that modulates hyperphosphorylation of tau comprising the steps of
- a) administering the drug to a transgenic mouse, the transgenic mouse comprising a transgene, said transgene comprising a polynucleotide encoding a human tau protein operably linked to at least a portion of a regulatory region of a mouse prion gene, wherein the transgenic mouse expresses hyperphosphorylated human tau protein; and
 - b) comparing the state of phosphorylation of tau in a second transgenic mouse to which the drug was not administered to the state of phosphorylation of tau in the transgenic mouse to which the drug has been administered, wherein a difference in phosphorylation indicates the drug modulates hyperphosphorylation of tau.
15. A method of screening for a drug for treatment of a neurodegenerative disease comprising the step of administering the


drug to a transgenic mouse which exhibits neurodegenerative disease characteristics, the transgenic mouse comprising a transgene, said transgene comprising a polynucleotide encoding a human tau protein operably linked to at least a portion of a regulatory region of a mouse prion gene, wherein the transgenic mouse expresses human tau protein, and wherein it is determined whether the drug at least partially abates at least one of the characteristics of the disease.

16. A method of screening for a drug that blocks hyperphosphorylation of tau comprising the step of administering the drug to a transgenic mouse, the transgenic mouse comprising a transgene, said transgene comprising a polynucleotide encoding a human tau protein operably linked to at least a portion of a regulatory region of a mouse prion gene, wherein the transgenic mouse expresses hyperphosphorylated human tau protein, and wherein it is determined whether the drug at least partially blocks hyperphosphorylation of tau in the transgenic mouse.
17. A method of screening for a drug that blocks formation of filamentous aggregates of tau comprising the step of administering the drug to a transgenic mouse, the transgenic mouse comprising a transgene, said transgene comprising a polynucleotide encoding a human tau protein operably linked to at least a portion of a regulatory region of a mouse prion gene, wherein the transgenic mouse expresses human tau protein forming filamentous aggregates, and wherein it is determined whether the drug at least partially blocks formation of filamentous aggregates of tau in the transgenic mouse.

Figure 1



2/2
Figure 2



SEQUENCE LISTING

<110> Pharmacia & Upjohn Company

<120> Transgenic Mouse Model Of Human Neurodegenerative Disease

<130> PHRM0301

<150> 60/177,319

<151> 2000-01-21

<160> 15

<170> PatentIn version 3.0

<210> 1

<211> 1152

<212> DNA

<213> Homo sapiens

<400> 1
atggctgagc cccgccagga gttcgaagtg atggaagatc acgctgggac gtacgggttg 60
ggggacagga aagatcaggg gggctacacc atgcaccaag accaagaggg tgacacggac 120
gctggcctga aagctgaaga agcaggcatt ggagacaccc ccagcctgga agacgaagct 180
gctggtcacg tgaccaaaagc tcgcatggtc agtaaaagca aagacgggac tggaaagcac 240
gacaaaaaag ccaagggggc tgatggtaaa acgaagatcg ccacaccgcg gggagcagcc 300
cctccaggcc agaagggcca ggccaacgcc accaggatcc cagcaaaaaa cccgcccgct 360
ccaaagacac caccagctc tgggtgaacct ccaaaatcag gggatcgacg cggctacagc 420
agcccccggc cccaggcac tcccggcagc cgctcccga ccccgctcct tccaacccca 480
cccacccggg agcccaagaa ggtggcagtg gtccgtactc caaccaagtc gccgtcttcc 540
gccaaagacc gcctgcagac agcccccgct cccatgccag acctgaagaa tgtaagttcc 600

2

aagatcggt cactgagaa cctgaagcac cagccgggag gcgggaaggt gtagataatt 660
 aataagaagc tggatcttag caacgtccag tccaagtgtg gctcaaagga caatatcaaa 720
 cagctcccg gaggcggcag tgtgcaaata gctacaaaac cagttgacct gagcaaggtg 780
 acctccaagt gtggctcatt aggcaacatc catcataaac caggaggtgg ctaggtggaa 840
 gtaaatctg agaagcttga cttcaaggac agagtccagt cgaagatttg gtccctggac 900
 aatatcacc acgtccctgg cggaggaaat aaaaagattg aaaccacaa gccgaccttc 960
 cgcgagaacg ccaaaagcaa gacagaccac gggcgggaga tegtgtacaa gtcccgagt 1020
 gtgtctgggg acacgtctcc acggcatctc agcaatgtct cctccaccgg cagcatcgac 1080
 atggtagact cgccccagct cgccacgcta gctgacgagg tgtctgcttc cctggccaa 1140
 cagggtttgt ga 1152

<210> 2

<211> 9990

<212> DNA

<213> Mus musculus

<400> 2
 ggcggccgcg acgatccaa aggcagcaaa aaggcagaga gggatgacct gggcccggt 60
 taagcatttg aaacttcaaa gctcaccctc aattacacac ttcttccaa aagtcacac 120
 ctctaattra gtgccactct ctgtgggcct acggagagta ttttcttct aactaccaca 180
 gttgtgagg aatttaatta aaactacaac ctctcccaa cctagatctt tcagccttct 240
 tgtactacca gagagggttc atacagcatt gttgtgactc cctattatac ttaaggggaa 300
 gctcacacaa agtccagagc cctccatacc ctgcaaatga agaagtacgt tctcaaatcc 360
 cttggagcag ggcctcactt tggcggcaca aactttaatt tctagacgga acggcatctc 420
 tacagaaaga aaagccatgg tatctgcatg ataagctga aaaggacctg ggcgaatctg 480
 cagctgacaa ttccagccat tgcctgcaact gcgagaaaac cctgctgatg gcagcattgt 540
 cagcatcacc tctccagga acaccggcca tcgagccagc aggacaattg ctgtgtctgg 600
 agtcaattca tetgcccagc acatcatact ctgggacctg cactaaccag atccaagcag 660
 ccttgaggaa gcatgtcttc tgggtgtgac tgatcccaag ggctgaccaac aaggtcctca 720
 cagaggcacc ttatgtcaac ctatctacca tgcacggtat aagacacatt ctctctgtg 780
 ctgtgtggac actgcatca cagcaacag aaaggaaact cactcactgt gctctgatgtg 840

gtggtgcttg ttatgggagc tctgggcatg tatggcacca tggcccatga ggactcctgt	900
ggggctatgc ccactctact cctctagaga ccatgaagag acggagaggg aagagcaagc	960
acagatgaca ggttagaact aaagaggagt gtcaggcgag cggacctgaa ctcacggctg	1020
ctcagcctga agtgggtgg ccactcgcac ctgggtatct gctgaaggt gcgtggatac	1080
cctctgtgcc cgtccagaag ttctctactg aagacagaaa tgctgtcca gtcatggaag	1140
aatgattggc agttccact tctcagacca ctgaatgggt cagaacaact actgggtgac	1200
cctaaggtat tcttcagcag atatgtgtga aaaatggaaa gaagatgggt agaaataaac	1260
ggttttagag gaaaaaact ctcacaaga tattataaaa agaaaagagc ttattatttg	1320
agcaagcatt caaccagaat gcacaccaca ggcagtcctg taaggagggt tgcagacagg	1380
aggagtgtcg ccttttatgt gagccagtag ataaggatgc tgtgcgtgtt tttagtaact	1440
ggtcttcagc ttgacagcac catttatcac atggtttaac ctataattcat ctggcgaatg	1500
aggctgtcac gtacttcctg attagcttta tctgaaatga gacaagcttc acatgttcac	1560
ggcaggagggt aatcctgctg cttagagaac agggctccat caagccagge tcctctcccc	1620
accaacacgg gtggttgaag agctatctct cctgggtgtg tgtgtttcag agatggctcc	1680
cagggttttg gtttggttg aattgggttt tggttttctt acctagccc agactagctt	1740
ggaattctct ggaagctgc aacggggagc tcagggtcag tgagagatcc tgtctcaaaa	1800
agcagggtga gaagtgttg aggaagacac ccagtggtta acctctgacc tccatatgtg	1860
catgcatgga cagcgtatga tacacatata cacacacaca cacacacaca cacacacaca	1920
cacacacaca cacacacaaa accagaaaaga atgaacgccc cctcccagc ttgtttacag	1980
tagatacaga gcactcgtaa aacatggggt gtaaaactgaa tgctgagagt aacttagatg	2040
agtaattaa gaaagaaag gaaagaaacc aggaaccga gagcaagtga ctggaagatc	2100
gttaggcaat cccacacccc tgctcgttga agttggaatg cttctctctt ctgcctcttg	2160
aagtctctta gaagtctag gatttcacaa ttagtctgtg gtggtttcaa tatgcttcac	2220
ccgtgttaag tggcactatt aggaacgtg tcttgttga aggaagggtg tcactgcata	2280
ggcgggcttt gaggtgtctt ccagtgtca agctctctcc agtgcagag aggcagacac	2340
ctgtgtcctg cagaagacag tctctgctg cetttgaatc aagatgtaga actcaagccc	2400
catgtctgcc tgaacctctg aaactgtaag ccagcccca ttaaatgttt tctttcaca	2460
gagtgccctt ggtcatgggt tctgttcaca gcaataaaac ctaactaag acagtcttaa	2520
atcaatgaaa agacctttaa ttattcattg aacaacacc atttctctgt atcaagtgtg	2580
cagtactag taagcaacta tagttctgca ccaggacct ttttgagaa atataccgat	2640

ccaaagcatgt tggcatctag attccaaagc caagacaccc gccacaccct tccatgcctt 2700
gggttctctg cagggcatctt ggcttcgggg atgtgtaatt caggcaccca ctggaatgca 2760
tggaaacaat taaaatagca tcatagaaga cattgcaatc ctaggggagaa actataccaa 2820
aactcagaac tatacctggt taagtgtaga aaagacgaaa ggaataaaac caggaatatt 2880
ttaaaatatt ttattgagc tcatgtgcat gggtaatttg cctgaaagta tgtctgtgta 2940
ccacatgcat ggctggctcc tgcagaggcc aaaagagagc atcagatctc ctgagctggt 3000
agtttcagaa gtttgtgagc taccacatgg gtgctggaaa caaaacccac gacatctgga 3060
agagcagcca gtgttcttaa ctactgagcc atcactcagg tcccaccatg aatgtttttc 3120
tttattcttc tctatatttt ctaatgtttt tattggaaat atacaacttt tgccacacat 3180
aacaatgac caaagaaatg aggtgagagg ggcagctggt caaatgctgc ctgggaaggc 3240
ttggccagcc ctggcttggc tgcccttggc tcagctggcc ctgacttggc tgtcccgtg 3300
ccagctgtca tctactgctt cataataagc tgcactttgg gctgaagggg tggctcagcc 3360
tttaaaaggt aggtctataa ccaaagttaag ttgcatttta ttgactag gttgaagggg 3420
gatctgaaac ttgctgtcaa tgttataaaa catttcatct tcaaatttgg tataggggtc 3480
atagaccaaa ggttctataa accccagaac agcaccactc cctagaataa agcaccata 3540
caagagccta tgggacactt tatagccaaa caaaaagcta tgtttgaaac ttcttttaca 3600
aggccttag tcccatctat aagggaagga gccccacttc gtaataaac cccactggtg 3660
acatttgaag gggacacatt caaactgtta caccatctta tatcatttgc acattagggt 3720
caaaactgtc gcagttgtca tttctaagaa gacagaagtt gtcaagcctg tgctttgagc 3780
cacaagtgtg acaacctact ttccaggcaag tcgctacttc cctaagactc taccccaata 3840
ggcctggggc ctggaatgtg ttttaacacag atgcaggctt ctgccttagt gcaggcttga 3900
gttctcatgt cctctctctt ttagctttcc gtctcaaggc gccctctctt agcagaaaaa 3960
atcagaggca taaagcatac atcaggggga agccagagtt ttcagaggga gttttgtgat 4020
ggccttttca gacatctctt gtcaagacta gtttgccctg ttctctttat taaatgaaag 4080
aaaaataatg cagtgttgca aattagcttt ggtaatggct ccaaccattg tcaggttcac 4140
agtctcattc cgccattcaa aacaacaaac ccaccacact ctctatgcag tgccgtaact 4200
cagaacagcc accaaacagc agaaagaggc tcccagactc ctctcagcct tgccataaac 4260
tcgcccggca catgcttatt ttaattattt taaattatgt cgtttctccc aacaatgacc 4320
tcccagtgcc ttggttgaca ggcttatacc attaaagccga ggcttgcata gcaacgataa 4380
ccaggtaggc tattattata accaggtagc tgccgagcta ctggtcgggc cccttttctc 4440

tctagaaacc	tctcaacccc	cacccaaaaa	agctttttatt	gccacttcct	agtcggtaga	4500
gagcagtcag	ccaatagata	tttgattctt	tgaggaaaaa	gctgagtttt	gatgtctttt	4560
aataagcct	ttcagagtc	ctctgtgggg	gaggccaggt	ggaagcgggg	tgsgaagctg	4620
gccecttacc	taagctaate	tagacaccc	cccactcttc	ccctgcccct	ttgacagatg	4680
cagtcacct	gatcacaatg	agtattctct	gaggcaggaa	ggcaaggctc	tggaagatgg	4740
tcaatgcctt	cattaagaac	ccagagtaaa	ggccaagcag	acaccaggac	cgcgaaatc	4800
taatttctact	gtaattgaa	catctcagcc	aaaggctgta	ttttccagcc	ctctcgtggc	4860
ctcttcccac	acaactgtca	acaactgtgt	gagcctaccc	atgtatgcgc	gctcacacac	4920
acacacacac	acacacacac	acacacacac	aggggtgggg	gacacaatga	ttacacaaga	4980
gtacttaata	aacaactata	attctctctgg	ctcggaatgt	tccttaccac	ccctctcttc	5040
cgatcccgga	tcttaatact	ggatacaaat	atttaatcca	aaaccaatct	tggtctgtgt	5100
aatgatcttc	agtgctctgc	cctcagcaag	aggacaggat	attatgtttt	ccctgtgatt	5160
tatgacctct	tctgtctcag	tatcggcagc	aattttattta	catggctttg	gagtggtgta	5220
tatgtgtagt	atggacatga	gggtgcatgt	caacctatgt	gtggaggcca	gaggtcaatg	5280
tcatgtcttc	cccaatcact	gcccagtggt	ccctggattc	caaactcagg	tcttcacgct	5340
tggaagctga	gccagtgccc	cagctcctaa	ccctcccttg	ttttaaaaag	gtctcattat	5400
gttgcccagg	tcagccttga	acttgagagt	ctcctgactg	caggctttca	ccgtgccaa	5460
tcagcaggca	tcttgaacaa	gaacatcatt	tcctttaagc	tgtttcaggc	tggtgttggt	5520
gggagctgtt	aaatgcagtg	catTTTTtcc	tttggaacac	ataaaagaaa	aaagtgatta	5580
aatgagctgg	gtgtggtggt	gcgagcttac	aatcctagaa	ctcaggagat	tgaggggagaa	5640
gcattgtctt	gagtttgagg	tcagcttaaa	ttacttagta	ggaacaccag	gccaattggt	5700
gctatgggat	tgcttccaaa	gataaagaaa	aaagggaagg	agagaaaaga	aaaagaaagg	5760
aaagaagggg	aaaagaaggga	atcagcagag	aataaataag	tcaacatgca	atggccaata	5820
tactttctag	gcctctaatt	cttttatagt	ttgtgggaaa	atgtcgaaaa	tcttcgttac	5880
caatttctag	ttaccaaagt	tcaacgatgg	cttctctgct	ccgttaggta	acctttcatt	5940
ttctcaacta	ccattatgt	aacgggagca	ttgggtactg	gatcagcttt	ccattaaaaga	6000
tgatttttat	agttgctgag	cgctgtcagg	gagtgctgac	actggggggcg	gtttaaacag	6060
atacaagcat	ttaaagccagt	ccggagcggg	gactcatccc	ccccacccc	cacccccccg	6120
cgagagacgc	ggcgcgagcca	ttggtgagca	tcacgccccg	ccccctcgcc	cgcttagttc	6180
ccgctgccc	cgcccccttc	cactcccgcc	tcccccgct	tgctggatca	gcagaccgat	6240

tctgggcgct	gcgtcgcatc	ggtggcaggc	aagcgggctg	ctgaagccag	gccttggcga	6300
gcactcagcc	ctcgtcgctc	aagctcggtc	cactcgcctc	ctcggggcct	tgagggccacg	6360
gggactagga	ctgggactgg	gaactggggc	gagctctggc	gggagggtgac	tgtacacccc	6420
ctgctgcgcg	actcctggag	gaaccgaatc	ccagggcagc	caggccggga	gccagccttt	6480
ccttcccgag	ccagattcac	agctcagcat	cgtcggggat	gggggtggca	tcttttgact	6540
gtccttggtc	gtttttctct	ctctttgtag	tagctacagc	gaacataatt	ttacctcgtt	6600
attccaccac	agtcattact	cccttcgaca	gtttcattct	caacgtcgcc	gtcgccttcc	6660
actgccctgt	ctaggcgctt	tcacgattgt	ctattttctt	gtactttgaa	taccgtgggt	6720
taatagcagt	tgcgggtcgc	cagaattctc	catttccctt	agagaaactc	ctgggagaat	6780
gggactaaag	acgtgcgaat	ttaattatat	cgcaaacagg	aatcaaaatt	ttgcattaaa	6840
atgccaaaca	tcttgaaaaa	ttactatttc	aatgaagaaa	aggaaactact	ttacctacac	6900
acacatccga	gagcttcgag	gaggcggaag	aaatagaaa	ctaagggtg	atttggggtg	6960
tatttgaaac	tgacacaagc	tttccatatt	atttatagca	gggactaaac	gatgagtcac	7020
tttctgaata	agatgcgaat	taaagcaagt	ttgtttgttg	tctttacatc	tattaaatag	7080
acagagacaa	tggcaacagc	aaccttaacc	tagaggttgc	ctgaaagtgt	caggtttggg	7140
aaacaagtgc	cctgcttaag	ggctagaaa	attgccttac	aaccaacaat	catgacttga	7200
cattgcctgg	ggttcccttt	gtctattcct	tttttaaaag	actagtgttt	attttatgtg	7260
catgagtgtt	ttgatccac	attcgcctgt	atacacacct	ggttctgtgg	aggtcaggag	7320
aggggtgctg	atgccctggc	actagagcct	tggatgggta	tgtgagcccc	tgccacaggg	7380
gagctcagaa	ccaatccag	gtcctctgga	agagcaacca	gagctcttaa	aacttctaag	7440
tatccctcca	tcccctttcc	atcatatttg	gaaaggagaa	aactgctacc	catgcctggc	7500
atttatttca	gagattaact	gtctgtgtaa	aacttgacat	tgaagtgcac	ctattctggt	7560
tcccattcat	acttagttga	gactactgta	agtcagttag	ggcttttttt	gtttgggtcc	7620
ttgggtagtt	tggagtgtgt	ttgtgagctc	attaacaggc	tttcaatatg	tagctggaat	7680
ttgctgtgta	gaccagacag	gcctcaaatt	tgtggcaatc	ctccctgcac	cttcccagaa	7740
tgccctggta	caggcataaa	ccaccgtgcc	cagcagtaaa	acaatctggt	gaggtattat	7800
tagtctgtgt	ctgtgaccca	gaacccccc	tcctggcaat	ttactgggaa	ggaacaacaa	7860
aagggctagg	ggagccatat	ggcctgcagt	tagagaaaa	tagatccaac	tgaaaaatca	7920
acctaaaggt	gtaaaagcca	agcagttaag	aaactgacaa	gctcatgatg	gaagccgagg	7980
ccatcgtgaa	cactcttcat	tttaggcccc	acgtatcact	ggggacaact	gagagtcaaa	8040

gtacaggtaa ggagaccaag gcttttcagg actcaggctg tctcagtgaa aagcccagaa 8100
 gagcagtaat tgaaagagct cagacgatgt gtctgatctc ccttgcttgt ttgttgctgt 8160
 attatttcca ctaacttatt tgggaggaaa aaaaacagtt cacaggcttc ttttcttgaa 8220
 atactgggga ttgctgggat cgaacccagg gataggtttt tagtttctaa aataacatag 8280
 atcatgcccc gtttgctttt tggaatatgt ttgcgctgcc cttatttcca tgttcaataa 8340
 ctgctccatt ttgcgtgact ctttagtatt ggtttgatga ttgcataatt agattagatt 8400
 gtatttcagt tctcagactt atttatcaat tctagtttct cttttttgtt gttttaaagg 8460
 actctgaggt atatttcaga actgaacat ttcaaccgag ctgaagcatt ctgccttctt 8520
 agtggtaact cgactatcag gtgaactttg aaccaggatg gctgagcccc gccaggagtt 8580
 cgaagtgatg gaagatcacg ctgggacgta cgggttgggg gacaggaagg atcagggggg 8640
 ctacaccatg caccaagacc aagaggggtga caggacgct ggccctgaaa ctgaagaagc 8700
 aggcatttga gacaccccca gcttgaaga cgaagctgct ggtcagctga cccaagctcg 8760
 catggctcagt aaaaacaaa acgggactgg aagcgtgac aaaaaagcca agggggctga 8820
 tggtaaaacg aagatcgcca caccgctggg agcagcccc ctgagccaga agggccaggc 8880
 caacgccacc aggatctcag caaaaacccc gccctgctca aagacaccac ccagctctgg 8940
 tgaacctcca aaatcagggg atcgcagcgg ctacagcag cccggctccc caggcactcc 9000
 cggcagccgc tcccgacccc cgtcccttcc aacccacccc acccgggagc ccaagaaggt 9060
 ggcagtggtc cgtactccac ccaagtcgac gtcttccgcc aagagccgcc tgcagacagc 9120
 ccccgctccc atgccagacc tgaagaatgt caagtccaag atcggctcca ctgagaacct 9180
 gaagcaccag ccggggagcg ggaaggtgca gataattaat aagaagctgg atcttagcaa 9240
 cgtccagtc aagtgtggct caaaggataa tatcaaacac gtcccgggag cgggcagtgt 9300
 gcaaatagtc tacaaccag ttgacctgag caaggtgacc tccaagtgtg gctcattagg 9360
 caacatccat cataaaccag gaggtggcca ggtggaagta aaatctgaga agcttgactt 9420
 caaggacaga gtccagtga agattgggtc cctggacaat ataccacag tccctggcgg 9480
 aggaataaaa aagattgaaa ccacaagct gaccttccgc gagaacgcca aagccaagac 9540
 agaccacggg cgggagatcg tgtacaagtc gccagtgggt tctggggaca cgtctccacg 9600
 gcatttcagc aatgtctcct ccaccggcag catcgacatg gtgactcgc ccagctcgc 9660
 cagctagct gacgaggtgt ctgctccct ggccaagcag ggtttgtgat caggccccctg 9720
 gggcggtcaa taattgtgga gaggagagaa tgagagagtg tggaaaaaaa aagaataatg 9780
 acccggtccc cgccctctgc cccagctgc tctcgcagt tcgggaattc ggatccagat 9840

cttatttaaag cagaacttgt ttattgcagc ttataaagggt tacaaataaa gcaatagcat 9900
cacaaatttc acaataaag catttttttc actgcattct agttgtggtt tgcctaaact 9960
catcaatgta tcttatcatg tctggtcgac 9990

<210> 3

<211> 25

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 3

agtaattgaa agagctcaga cgatg

25

<210> 4

<211> 23

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 4

tgtcaccttc ttggtcttgg tgc

23

<210> 5

<211> 22

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 5

gtactccacc caagtcgccc tc

22

<210> 6

<211> 23

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 6

gcagcagcat cgaagcttct cag

23

<210> 7

<211> 48

<212> DNA

<213> Artificial

<220>

<223> Missense

<400> 7

gcagcagcat cgaagcttct cagattttac ttccatctgg ccaectcc

48

<210> 8

<211> 20

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 8

ccgccaaagag ccgcctgcag

20

<210> 9

<211> 61

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 9

gcagcagcat cgaagctttt cagattttac ttccacctgg ccacctctta gtttatgatg 60
g 61

<210> 10

<211> 1152

<212> DNA

<213> Homo sapiens

<400> 10

atggctgagc cccgccagga gtccgaagtg atggaagatc acgctgggac gtacgggttg 60
ggggacagga aagatcaggg gggctacacc atgcaccaag accaagaggg tgacacggac 120
gtctggcctga aagctgaaga agcaggcatt ggagacaccc ccagcctgga agacgaagct 180
gtctggtcacg tgacccaagc tcgcatggtc agtaaaagca aagacgggac tggaaagcgt 240
gacaaaaaac ccaagggggc tgatggtaaa acgaagatcg ccacaccgag gggagcagcc 300
cctccaggcc agaagggcca ggccaacgcc accaggattc cagcaaaaac cccgcccgct 360
ccaaagacac caccagctc tggatgaacct ccaaaatcag gggatcgag cggtctacagc 420
agccccggct cccagggcac tcccggcagc cgctcccgca ccccgctcct tccaaaccca 480
cccacccggg agcccaagaa ggtggcagtg gtccgtactc cacccaagtc gccgtcttcc 540
gccaaagacc gcctgcagac agcccccgct cccatgccag acctgaagaa tgtcaagtcc 600
aagatcggct ccactgagaa cctgaagcac cagccgggag gcgggaaggt gcagataatt 660
aataagaagc tggatcttag caacgtccag tccaagtgtg gctcaaagga taatatcaaa 720
cacgtcccgg gaggcggcag tgtgcaaata gtctacaaac cagttgacct gagcaaggtg 780
acctccaaagt gtggtctatt aggcacacac catcataaac caggaggtgg ccagatggaa 840
gtaaaaatct agaagcttga cttcaaggac agagtccagt cgaagatttg gtcctctggac 900
aataatcacc acgtccctgg cggagggaaat aaaaagattg aaaccacaa gctgaccttc 960
cgcgagaacg ccaagccaa gacagaccac ggggaggaga tcgtgtacaa gtcgcagtg 1020
gtgtctgggg acacgtctcc acggcatctc agcaatgtct cctccaccgg cagcatcgac 1080

11

atggttagact cgccccagct cgccacgcta gctgacgagg tgtctgcctc cctggccaag 1140
cagggtttgt ga 1152

<210> 11

<211> 1152

<212> DNA

<213> Homo sapiens

<400> 11
atggctgagc cccgccagga gtctgaagtg atggaagatc acgctgggac gtacgggttg 60
ggggacagga aagatcaggg gggctacacc atgcaccaag accaagaggg tgacacggac 120
gctggcctga aagctgaaga agcaggcatt ggagacaccc ccagcctgga agacgaagct 180
gctggtcacg tgaccaagc tcgcatggtc agtaaaagca aagacgggac tggaaagcga 240
gacaaaaaag ccaagggggc tgatggtaaa acgaagatcg ccacaccgag gggagcagcc 300
cctccaggcc agaagggcca ggccaacgcc accaggatcg cagcaaaaac cccgcccgct 360
ccaaagacac caccagctc tggtgaaacct ccaaaatcag gggatcgagc cggctacagc 420
agccccggct ccccgaggac tcccggcagc cgctcccgca ccccgctcct tccaacccca 480
cccacccggg agccccagaa ggtggcagtg gtccgtactc cacccaagtc gccgtcttcc 540
gccaagagcc gcctgcagac agcccccggt cccatgccag acctgaagaa tgtcaagtcc 600
aagatcggtc ccatcgagaa cctgaagcac cagccgggag gcgggaaggt gcagataatt 660
aataagaagc tggatcttag caacgtccag tccaagtgtg gctcaaaagga taatatcaaa 720
cacgtcccgg gaggcggcag tgtgcaata gtctacaaaac cagttgacct gagcaagggt 780
acctccaagt gtggctcatt aggcacacac catcataaac taggaggtgg ccaggtggaa 840
gtaaaatctg agaagcttga cttaaggac agagtcacgt cgaagattgg gtccctggac 900
aatatcacc cagtcctcgg cggaggaaat aaaaagattg aaaccacaaa gctgaccttc 960
cgcgagaacg ccaaagccaa gacagaccac ggggcggaga tcgtgtacaa gtccgcagtg 1020
gtgtctgggg acacgtctcc acggcatctc agcaatgtct cctccaccgg cagcatcgac 1080
atggttagact cgccccagct cgccacgcta gctgacgagg tgtctgcctc cctggccaag 1140
cagggtttgt ga 1152

<210> 12

<211> 19

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 12

gcattggaga cacccccag

19

<210> 13

<211> 21

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 13

gcttttactg accatgcgag c

21

<210> 14

<211> 25

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 14

ctggaagacg aagctgctgg tcacg

25

<210> 15

<211> 9990

<212> DNA

<213> Artificial

<220>

<223> PrP/tau transgene construct

<400> 15

```

ggcggccgcg acggatccaa aggcagcaaa aaggcagaga gggtgatact gggcctggct    62
taagcatttg aaacttcaaa gctcaccccc aattacacac ttcttccaac aagccacac    120
ctcctaatta gtgccactct ctgtgggect acggagagta ttttcattct aactaccaca    180
gtgtgtgagg aatttaatta aaactacaac cttatcccaa cctagatctt tcagcctttc    240
tgtactacca gagaggggtc atacagcatt gttgtgactc ccattataac ttaaggga    300
gctcacacaa agtccagagc cctccatacc ctgcaaatga agaagtacgt tctcaaatcc    360
cttgagcagc ggcctcactt tggcggcaca aactttaatt tctagacgga acggcctctc    420
tacagaaaga aaagccatgg tatctgcatg ataagtctga aaaggacctg ggcaaatctg    480
cagctgacaa ttccagccat tgctgccact gcgagaaaaa cctgctgatg gcagcattgt    540
cagcatcatc tctccagga acacgggcca tcgagccacg aggacaattg ctgctgctgg    600
agtcaattca tctgccagcc acatcatact ctggggaccgt cactaaccag atccaagcag    660
ccttgaggaa gcatgtcttc tgggtgtgac tgatcccaag ggctgacaac aaggtcctca    720
cagaggcadc ttatgtcaac ctatctacca tgcacgggat aagacacatt ctctctgtg    780
ctgtgtggac actgccatca cagcacaacg aaaggaaact cactcactgt gctctgatgt    840
gtggtgcttg ttaggggagt tctgggcatg tatggcacca tcgcccatga ggactcctgt    900
ggggtcatgc ccactctact cctctagaga ccatgaagag atggagaggg aagagcaagc    960
acagatgaca ggctagaact aaagaggagt gtcaggtgag cggacctgaa ctccagcgtg    1020
ctcagcctga agtgggtgtg ccatctgcat ctggatatct gtctgaaggt gcgtggatac    1080
cctctgtgcc cgtccagaag ttctctactg aagacagaaa tgctgtcca gtcattggaag    1140
aatgattggc agttcccact tctcagacca ctgaatgggt cagaacaact actgggtgac    1200
cctaagggtat tcttcagcag atatgtgtga aaatggaaa gaagatgggt agaaaataac    1260
ggttttagag gaaaaaaact ctcaaaaaga tattataaaa agaaaaagac ttattatttg    1320
agcaagcatt caaccagaat gcacaccaca ggcagctctc taaggagtg tgcagacagg    1380
aggagtgtcg ccttttatgt gagccagtag ataaggatgc tgtgctgtgt tttagtaact    1440
ggtcttcagc ttgacagcac catttatcac atggtttaac ctaaattcat ctggcgaatg    1500
aggctgtcac gtaactcctg attagcttta tctgaaatga gacaagcttc acatgttcac    1560
ggcaggagggt aatcctgctg cttagagaac agggctccatc caagccaggc tctctctccc    1620
accaacacgg gtgggtgaag agctatctct cctgggtgtg tgtgtttcag agatggctcc    1680

```

cagggtttttg gcttggtttg aattgggttt tgggttttctt accttagccc agactagcct 1740
 ggaattctct ggaagcctgc aacggggagc tcagggttcag tgagagatcc tgcctcaaaa 1800
 agcagggtga gaagtgatcg aggaagacac cccagtgtta acctctgacc tccatattcg 1860
 catgcatgga cgcgcatgga tacacatata cacacacaca cacacacaca cacacacaca 1920
 cacacacaca cacacacaaa accagaaaaga atgaacgccc cctctccagc ttgtttacag 1980
 tagatacaga gcaactcgtta aacatgggggt gtaaaactgaa tgcctgagagt agcttagatg 2040
 agtaattaag gaaggaagag gaaagaaaacc aggaaacctga gagcaagtga ctggaagatc 2100
 gttaggcaat cctccacccc tgcctcgttg agttggaatg ctttcttctt ctgcctcttg 2160
 aagttcttta gaagtgcctag gatttcacaa ttagctctgtg gtgtgttcaa tatgcttcac 2220
 ccgtggtaag tggcactatt aggaacgtg tccttggtga aggaagggtg tcaactgcata 2280
 ggcgggcttt gaggtgtctt ccagtgtcga agctcctccc agtgcagag aggcagacac 2340
 ctgttgctcg cagaagacag tctctcgtcg cctttgaatc aagatgtaga actcaagccc 2400
 catgtctgcg tgaacctctg aaactgtaag ccagccccc aaataatgtt tctttcacaa 2460
 gagtgcctt ggtcatggcg tctgttcaca gcaataaaac cctaactaag acagtcttaa 2520
 atcaatgaaa agacctttaa ttattcattg aacaaacacc attttcttgt atcaagttgg 2580
 cagtactag taagcaacta tagttctgca ccagggaact ttttgagaa atataccgat 2640
 ccaagcatgt tggcatctag attccaaagc caagacacct gccacacct tccatgcctt 2700
 cgggtccttg cagggcactt ggcttcgggg atgtgtatc caggcaccca ctggaatgca 2760
 tggaaacaat taaaatagca tcatagaaga cattgcaatc ctaggagaaa actataccaa 2820
 aactcagaac tatacttggt taagtgtaga aaagacgaaa ggaataaaac caggaatat 2880
 ttaaaatatt ttattgagc tcatgtgcat gggtaatttg cctgaaaagta tgtctgtgta 2940
 ccacatgat ggctggctcc tgcagaggcc aaaagagagc atcagatctc cttagctgg 3000
 agtttcagaa gtttgtgagc taccacatgg gtgctggaaa caaaaccag gacactgga 3060
 agagcagcca gtgtcttaa ctactgagcc atcaactagg tccaccatg aatgtttttc 3120
 ttattcttc tctatatttt ctaatgtttt tattggaat atacaacttt tgccacacat 3180
 aacaaatg caaagaaatg aggtgagagg ggcagctgtt caaatgctgc ctggaaggc 3240
 ttggccagcc ctggctggc tgccctggc tcagctggc ctgacttggc tgtcccggtg 3300
 ccagctgca tctactgctt cataataagc tgcactttgg gctgaagggg tggctcagcc 3360
 ttaagggt aggtcctaaa ccaagtaag ttgcatttta ttgcaactag gttgaagggg 3420
 gatctgaaac ttgctgtcaa tgttataaaa cattttatct tcaaatgtg tatagggtgc 3480

atagacccaaa	ggtttctataa	accccagaac	agcaccaccct	cctagaaaata	agcaccata	3540
caagagcccta	tgggacactt	tatagccaaa	caaaaagcta	tgtttgaaac	ttcctttaca	3600
agggcctgag	tcccattcat	aagggaagga	gcccaccttc	gtaataacac	cccactgggtg	3660
acatttgaa	gggacacatt	caaaactgtaa	caccatctta	tatcatttgc	acattaggggt	3720
caaaactgtgc	cacgtttgca	tttctaagaa	gacagaagtt	gtcaagcctg	tgtcttgagc	3780
cacaagtgtg	acaacctact	ttcaggcaag	tgcctacttc	cctaagactc	taccccaata	3840
ggcctgggggt	ctggaatgtg	tttaacacag	atgcaggctt	ctgccttagt	gcaggcttga	3900
gttctcatgt	ccctctctct	ttagctttcc	gtctcaaggg	gcctctcctt	agcagaaaaa	3960
atcagaggca	taaaagcatac	atcaggggga	agccagagtt	ttcagaggga	gtttttgtgat	4020
ggccttttca	gagcattctt	gtcaagacta	gtttgcctcg	ttctctttat	taaatgaaa	4080
aaaaataatg	cagtgttgca	aattagcttt	ggtaatggct	ccaaccattg	tcagggttcac	4140
agtctcattc	gcgcattcaa	aacaacaaac	ccaccacact	ctctatgcag	tgccgtaact	4200
cagaacagcc	accaaacagc	agaaagaggg	tcccgcactc	ctctcagcct	tgccataaac	4260
tgcgcggcca	catgcttatt	ttaaattatt	taaattatgt	cgtttctccc	aacaatgacc	4320
tccaagtgc	tgtgttgaca	ggcttatacc	attaagccga	ggcttgcata	gcaacgataa	4380
ccaggtaggc	tattattata	accaggtagc	tgccgagcta	ctggctgggtc	cccttttgtc	4440
tctagaaacc	tctcaacccc	cacccaaaaa	agcttttatt	gccacttcct	agtggttaga	4500
gagcagtcag	ccaatagata	tttgattctt	tgaggaaaaa	gctgagtttt	gatgtctttt	4560
aatcaagcct	ttcagagtcc	ctctgtgggg	gaggccaggt	ggaagcgggg	tgggaaagctg	4620
gtcccttacc	taagctaata	tagacacct	cccactcttc	ccctgccttc	ttgacagatg	4680
cagtcatcct	gatcacaaatg	agtattctct	gaggcaggaa	ggcaaggctc	tggaaagtgg	4740
tcaatgcctt	cattaagaac	ccagagtaaa	ggtcaagcag	acaccagcac	cgtcgaaatc	4800
taatttcaat	gtaattgaat	catctcagcc	aaaggctgta	ttttccagcc	ctctcgtggc	4860
ctcttcccca	acaactgtca	acaactgtgt	gagcctaccc	atgtatgcgc	gctcacacac	4920
acacacacac	acacacacac	acacacacac	aggggtggggg	gacacaatga	ttacacaaga	4980
tacttaata	aacaactata	attctcctgg	ctcgatagtt	tccttaccac	cctctcctcc	5040
tggatccgga	tcctaatact	ggatacaaat	atttaatcca	aacccaatct	tgtgtctggt	5100
aatgatcttc	agtgctctgc	cctcagcaag	aggacaggat	attatgtttt	cctctgtgatt	5160
tatgacctct	ctgtctcag	tatcggcagc	aattttatta	catggctttg	gagtgcttta	5220
tatgtgtagt	atggacatga	gggtgcatgt	caacctatgt	gtggaggcca	gaggtcaatg	5280

tcattgtcttc cccaatcact gccagtggt ccttggttc caaactcagg tcctcacgct	5340
tgggaactga gccagtgccc cagctccctaa cctccccctg ttttaaaaag gtctcattat	5400
gttgcccagg tcagccttga acttgagagt ctctcgactg caggctttca cctgtccaag	5460
tcagcaggca tcttgaacaa gaacatcatt tcctttaagc tgttcaggc tgtgtttggt	5520
gggagctgtt aaatgcagtg catttttttc tttggacaca ataaaaaaa aaagtgttta	5580
aatgagttgg gtgtggtggt gcgagctctac aatcctagaa ctcaggagat tgaggggagaa	5640
gcattgctct gagtttgagg tcagcttaaa ttacttagta ggaaccaccg gccaaattgg	5700
gctatgggat tgtctccaaa gataaagaaa aaagggaagg agagaaaaga aaaagaaagg	5760
aaagaagggg aaaagaagga atcagcagag aataaataag tcaacatgca atggccaata	5820
tactttctag gccctcaatt cttttatagt ttgtgggaaa atgtcgaaaa tcttcgttac	5880
caatttcttg ttaccaaaagt tcaacgatgg ctctctcgct ccgttaggta acctttcatt	5940
ttctcaacta cccattatgt aacgggagca ttgggtactg gatcagctct ccattaaaga	6000
tgatttttat agttgctgag cgtcgctcagg gagtgctgac actggggggc gtttaaacag	6060
atacaagcat ttaagccagt ccggagcggg gactcatccc cccccccccc cccccccccc	6120
cgagagacgc ggcgcggcca ttggtgagca tcacgccccg cccctcgccc cgcttagttc	6180
cgccctgccc cgcccccttc cactcccggc tcccccgct tgcggataca gcagaccgat	6240
tctgggcgct gcgtcgcatc ggtggcaggg aagcgggctg ctgaagccag gccctggcga	6300
gcactcagcc ttccgctgctc aagctcggct cactgcgect ctgggggccc tgaggccacg	6360
gggactagga ctgggactgg gactggggct gagtctggct gggagggtgac tgtacacccc	6420
ctgctcgcg actcctggag gaaccgaatc ccagggcagc caggccggga gccagccttt	6480
ccttcccgag ccagattcac agctcagcat cgtggggat ggggttgga tcttttgact	6540
gtccttggtt gttttcttct ctcttgtag tagctacagc gaacataatt ttacctgct	6600
attccaccac agtcattact ccttgccaca gtttcattct caacgtcgcc gtgcgcttc	6660
actgcctgt ctaggcggtt tcatgattgt ctattttctt gtactttgaa taccgtggt	6720
taatagcagt tgcgggtgag cagaattctc catttcotta agagaaactc ctgggagaat	6780
gggactaaag acgtgcaaat ttaattatat cgcaaacagg aatcaaaatt ttgcattaaa	6840
atgccaacaa tcttgaaaaa ttaactattc aatgaagaaa aggaactact ttactacac	6900
acacatccga gagcttcgag gaggcgaagg aaatagaaag ctaagggatg atttgggtg	6960
tatttgaaac tgacacaagc ttccatatt atttatagca gggactaaac gatgagtcac	7020
ttcttgaata agatgcaaat taaagcaagt ttgtttgttg tctttacac tattaatat	7080

acagagacaa	tggcaacagc	aaccctaacc	tagagggtgc	ctgaaagtgt	caggtttggg	7140
aacaagtggc	cctgcttaag	ggc:agaaag	attgctttac	aaccaacaat	ca:gacttga	7200
cattgectgg	ggttcccttt	gtctattcct	tttttaaaag	actagtgttt	at:cttatgtg	7260
catgagtgtt	ttgcatccac	attcgccctg	atacacacct	ggttctgtgg	aggtcaggag	7320
aggggtctgg	atgccctggc	actagagcct	tggatgggta	tgtgagcccc	tgcacacagg	7380
gagctcagaa	ccaaaaccag	gtcctctgga	agagcaacca	gagctcttaa	aacctctaa	7440
tatccctcca	tccctcttcc	atcataattg	gaaaggagaa	aactgctacc	catgacctgc	7500
atttatttca	gagattaact	gtctgtgtaa	aacttgacat	tgaagtgcac	ctattctgtt	7560
tccattccat	acttagttga	gactactgta	agtcagttag	ggcttttttt	gtctgggtcc	7620
ttggttagtt	tggagtgtgt	ttgtgagctc	attaacaggc	tttcaatatg	tagctggaat	7680
ttgtctgtga	gaccagacag	gcttcaaatt	tgtggcaatc	ctccctgcac	ctcccagaa	7740
tgccctggta	caggcataaa	ccaccgtgcc	cagcagtaaa	acaatctggt	gaggtattat	7800
tagtcgtgtg	ctgtgaccca	gaaaccccac	tcttggcaat	ttactgggaa	ggaaacaaca	7860
aagggtctagg	ggagccatat	ggcctgcagt	tagagaaaaa	tagatccaac	tgaaaaaatca	7920
acctaaagg	gtaaaagcca	agcagttaag	aaactgacaa	gctcatgatg	gaagccgagg	7980
ccatcgtgaa	cactcttcat	tttaggcccc	acgtatcact	ggggacaact	gagagtcaca	8040
gtacaggtaa	ggagaccaag	gcttttcagg	actcaggctg	tctcagttaa	aagcccagaa	8100
gagcagtaat	tgaagagctc	cagacgatgt	gtctgatctc	ctctgtttgt	ttgttgtgtg	8160
attatttcca	ctaacttatt	tgggaggaaa	aaaaacagtt	cacaggcttc	ttttcttgaa	8220
atactgggga	ttgctgggat	cgaacccagg	gataggtttt	tagtttctaa	aataacatag	8280
atcatgccct	gtttgctttt	tggaaatatg	ttgcgtgcc	cttattttca	tg:tcaataa	8340
ctgctccatt	ttgcgtgact	ctttagtatt	ggtttgatga	tttgcattat	agatttagatt	8400
gtatttcagt	tctcagactt	atttataaat	tctagttttc	tcttttttgt	gttttaaaag	8460
actcttgagt	atatttcaga	actgaacct	ttcaaccgag	ctgaagcatt	ctgccttctc	8520
agtggtaacct	cgactatcag	gtgaactttg	aaccaggatg	gctgagcccc	gccaggagtt	8580
cgaagtcatg	gaagatcacg	ctgggactga	cgggttgggg	gacaggaaag	atcagggggg	8640
ctacaccatg	caccaagacc	aagagggtga	cacggacgct	ggcctgaaag	ctgaagaagc	8700
aggcatttga	gacaccccca	gcctggaaag	cgaagctgct	ggtcacgtga	cccaagctcg	8760
catggctcagt	aaaagcaaa	acgggactgg	aagcgtgac	aaaaaagcca	agggggctga	8820
tggtaaaaag	aagatcgcca	caccgcgggg	agcagccctc	ccaggccaga	agggccaggc	8880

caacgccacc	aggattccag	caaaaacccc	gcccgctcca	aagacaccac	ccagctctgg	8940
tgaacctcca	aaatcagggg	atcgcagcgg	ctacagcagc	cccggtcccc	caggcactcc	9000
cggcagccgc	tcccgacccc	cgtcccttcc	aacccacccc	acccgggagc	ccaagaaggt	9060
ggcagtggtc	cgtactccac	ccaagtcgcc	gtcttccgcc	aagagccgcc	tcgagacagc	9120
ccccgtcccc	atgccagacc	tgaagaatgt	caagtccaag	atcggtccca	ctgagaacct	9180
gaagcaccag	ccgggaggcg	ggaaggtgca	gataattaat	aagaagctgg	atcttagcaa	9240
cgccagtc	aagtgtggct	caaaggataa	tatcaaacac	gtcccgggag	gcgcagctgt	9300
gcaaatagtc	tacaaaccag	ttgacctgag	caaggtgacc	tccaagtgtg	gtctattagg	9360
caacatccat	cataaaccag	gaggtggcca	ggtggaagta	aaatctgaga	agcttgactt	9420
caaggacaga	gtccagtcga	agattgggtc	cctggacaat	atcacccacg	tccctggcgg	9480
aggaaataaa	aagattgaaa	cccacaagct	gaccttccgc	gagaacgcca	aagccaagac	9540
agaccacggg	gcggagatcg	tgtacaagtc	gccagtgggt	tctggggaca	cgtctccacg	9600
gcctctcagc	aatgtctect	ccaccggcag	catcgacatg	gtagactcgc	cccagctcgc	9660
cacgctagct	gacgaggtgt	ctgectccct	ggccaagcag	ggtttgtgat	caggccccctg	9720
gggcggtcaa	taatttgtga	gaggagagaa	tgagagagtg	tggaaaaaaa	aagaataatg	9780
acccggcccc	cgccctctgc	ccccagctgc	tctctgcagt	tcgggaattc	ggatccagat	9840
cttattaag	cagaacttgt	ttattgcagc	ttataatggt	tacaaataaa	gcaatagcat	9900
cacaaatttc	acaaataaag	catttttttc	actgcattct	agttgtggtt	tgctcaaaact	9960
catcaatgta	tcttatcatg	tctggtcgac				9990